



VOLUME 131

This publication represents the views and expert opinions of an IARC Working Group on the Identification of Carcinogenic Hazards to Humans, which met remotely, 2–18 March 2022

LYON, FRANCE - 2023

IARC MONOGRAPHS
ON THE IDENTIFICATION
OF CARCINOGENIC HAZARDS
TO HUMANS

SUMMARY OF FINAL EVALUATIONS

Summary of final evaluations for Volume 131

Agent	Evidence stream			Overall evaluation
	Cancer in humans	Cancer in experimental animals	Mechanistic evidence	_
Cobalt metal (without tungsten carbide or other metal alloys)	Inadequate	Sufficient	Strong	Group 2A
Soluble cobalt(II) salts	Inadequate	Sufficient ^a Limited ^b	Strong [,]	Group 2A
Cobalt(II) oxide	Inadequate	Sufficient	Limited	Group 2B
Cobalt(II,III) oxide	Inadequate	Inadequate	Limited	Group 3
Cobalt(II) sulfide	Inadequate	Limited	Inadequate,	Group 3
Other cobalt(II) compounds	Inadequate	Inadequate	Inadequate	Group 3
Trivalent antimony	Limited	Sufficient ^c	Strong	Group 2A
Pentavalent antimony	Inadequate	Inadequate	Limited	Group 3
Weapons-grade tungsten (with nickel and cobalt) alloy	Inadequate	Sufficient	Limited	Group 2B

 $^{{\}tt a}$ There is $\it sufficient\ evidence$ in experimental animals for the carcinogenicity of cobalt(II) sulfate.

 $^{^{\}mathrm{b}}$ There is $\mathit{limited\ evidence}$ in experimental animals for the carcinogenicity of cobalt(II) chloride.

^cThere is *sufficient evidence* in experimental animals for the carcinogenicity of antimony trioxide.